Top
Summary
All studies
Exclusions
Mortality
Ventilation
ICU
Hospitalization
Serious outcomes
Recovery
Cases
Viral clearance
RCTs
RCT mortality
Peer-reviewed
All outcomes

Feedback
Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Other
Feedback
Home
Top
All nitazoxanide studies
 
Feedback
Home
c19early.org COVID-19 treatment researchNitazoxanideNitazoxanide (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis

Outcomes in COVID-19 nitazoxanide studies

Home
Post
Share
@CovidAnalysis
StudiesStudies
FeedbackFeedback
All studies   Exclusions   Mortality   Ventilation   ICU   Hospitalization   Serious outcomes   Recovery   Cases   Viral clearance   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies 35% 14 3,632 Improvement, Studies, Patients Relative Risk Mortality 42% 6 1,877 Ventilation 82% 3 588 ICU admission 28% 3 841 Hospitalization 61% 6 1,864 Progression -16% 3 1,007 Recovery 6% 6 1,335 Cases 13% 2 1,747 Viral clearance 38% 7 865 RCTs 17% 11 2,981 RCT mortality 28% 4 1,339 Peer-reviewed 50% 11 2,644 Prophylaxis 44% 2 531 Early 29% 8 2,545 Late 12% 4 556 Nitazoxanide for COVID-19 c19early.org November 2024 after exclusions Favorsnitazoxanide Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Cadegiani 88% 0.12 [0.01-2.52] death 0/357 2/137 Elalfy 87% 0.13 [0.06-0.27] viral+ 7/62 44/51 CT​2​ Silva (SB RCT) 26% 0.74 [0.38-1.41] viral+ 23 (n) 13 (n) Rossignol (DB RCT) -206% 3.06 [0.13-74.6] death 1/184 0/195 ANTICOV ANTICOV (RCT) -188% 2.88 [1.05-7.85] progression 15/462 5/443 OT​1​ CT​2​ Medhat (RCT) 56% 0.44 [0.22-0.88] viral+ 77 (n) 73 (n) Chandiwana (RCT) -13% 1.13 [0.23-5.46] progression 37 (n) 39 (n) CT​2​ FANTAZE Smith (DB RCT) unknown, >1.5 years late 120 (total) Tau​2​ = 1.04, I​2​ = 78.3%, p = 0.46 Early treatment 29% 0.71 [0.29-1.73] 25/1,396 51/1,149 29% lower risk Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Improvement, RR [CI] Treatment Control Calderón 68% 0.32 [0.04-2.49] death 1/17 5/27 OT​1​ Fowotade (RCT) -11% 1.11 [0.61-2.03] no recov. 31 (n) 26 (n) CT​2​ Rocco (DB RCT) -5% 1.05 [0.30-3.50] death 6/202 5/203 Tau​2​ = 0.03, I​2​ = 7.9%, p = 0.65 Late treatment 12% 0.88 [0.52-1.50] 9/275 16/281 12% lower risk COVER Sokhela (RCT) 66% 0.34 [0.01-8.41] death 0/240 1/265 Improvement, RR [CI] Treatment Control Romark (DB RCT) 43% 0.57 [0.35-0.92] progression 13 (n) 13 (n) Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.017 Prophylaxis 44% 0.56 [0.35-0.90] 0/253 1/278 44% lower risk All studies 35% 0.65 [0.39-1.08] 34/1,924 68/1,708 35% lower risk 14 nitazoxanide COVID-19 studies (+1 unreported RCT) c19early.org November 2024 Tau​2​ = 0.47, I​2​ = 67.0%, p = 0.097 Effect extraction pre-specified(most serious outcome) ​1​ OT: comparison with other treatment​2​ CT: study uses combined treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Cadegiani 88% 0.12 [0.01-2.52] death 0/357 2/137 Elalfy 87% 0.13 [0.06-0.27] viral+ 7/62 44/51 CT​2​ Silva (SB RCT) 26% 0.74 [0.38-1.41] viral+ 23 (n) 13 (n) Rossignol (DB RCT) -206% 3.06 [0.13-74.6] death 1/184 0/195 Medhat (RCT) 56% 0.44 [0.22-0.88] viral+ 77 (n) 73 (n) Chandiwana (RCT) -13% 1.13 [0.23-5.46] progression 37 (n) 39 (n) CT​2​ Tau​2​ = 0.67, I​2​ = 69.3%, p = 0.12 Early treatment 49% 0.51 [0.22-1.18] 10/934 46/706 49% lower risk Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Improvement, RR [CI] Treatment Control Calderón 68% 0.32 [0.04-2.49] death 1/17 5/27 OT​1​ Fowotade (RCT) -11% 1.11 [0.61-2.03] no recov. 31 (n) 26 (n) CT​2​ Rocco (DB RCT) -5% 1.05 [0.30-3.50] death 6/202 5/203 Tau​2​ = 0.03, I​2​ = 7.9%, p = 0.65 Late treatment 12% 0.88 [0.52-1.50] 9/275 16/281 12% lower risk COVER Sokhela (RCT) 66% 0.34 [0.01-8.41] death 0/240 1/265 Improvement, RR [CI] Treatment Control Romark (DB RCT) 43% 0.57 [0.35-0.92] progression 13 (n) 13 (n) Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.017 Prophylaxis 44% 0.56 [0.35-0.90] 0/253 1/278 44% lower risk All studies 44% 0.56 [0.35-0.90] 19/1,462 63/1,265 44% lower risk 13 nitazoxanide COVID-19 studies after exclusions c19early.org November 2024 Tau​2​ = 0.34, I​2​ = 59.6%, p = 0.017 Effect extraction pre-specified(most serious outcome) ​1​ OT: comparison with other treatment​2​ CT: study uses combined treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cadegiani 88% 0.12 [0.01-2.52] 0/357 2/137 Improvement, RR [CI] Treatment Control Rossignol (DB RCT) -206% 3.06 [0.13-74.6] 1/184 0/195 Tau​2​ = 2.67, I​2​ = 51.4%, p = 0.75 Early treatment 41% 0.59 [0.02-13.8] 1/541 2/332 41% lower risk Blum (DB RCT) 67% 0.33 [0.07-1.50] 2/25 6/25 Improvement, RR [CI] Treatment Control Calderón 68% 0.32 [0.04-2.49] 1/17 5/27 OT​1​ Rocco (DB RCT) -5% 1.05 [0.30-3.50] 6/202 5/203 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.23 Late treatment 40% 0.60 [0.26-1.39] 9/244 16/255 40% lower risk COVER Sokhela (RCT) 66% 0.34 [0.01-8.41] 0/240 1/265 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Prophylaxis 66% 0.34 [0.01-8.41] 0/240 1/265 66% lower risk All studies 42% 0.58 [0.27-1.24] 10/1,025 19/852 42% lower risk 6 nitazoxanide COVID-19 mortality results c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.16 ​1​ OT: comparison with other treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Cadegiani 97% 0.03 [0.00-0.51] 0/357 9/137 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.015 Early treatment 97% 0.03 [0.00-0.51] 0/357 9/137 97% lower risk Blum (DB RCT) 62% 0.38 [0.11-1.25] 3/25 8/25 Improvement, RR [CI] Treatment Control Calderón 87% 0.13 [0.01-2.33] 0/17 4/27 OT​1​ Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.044 Late treatment 68% 0.32 [0.11-0.97] 3/42 12/52 68% lower risk All studies 82% 0.18 [0.04-0.76] 3/399 21/189 82% lower risk 3 nitazoxanide COVID-19 mechanical ventilation results c19early.org November 2024 Tau​2​ = 0.50, I​2​ = 27.5%, p = 0.019 ​1​ OT: comparison with other treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] 2/194 0/198 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.3 Early treatment -404% 5.04 [0.24-104] 2/194 0/198 404% higher risk Calderón 59% 0.41 [0.25-0.59] 0/17 16/27 OT​1​ Improvement, RR [CI] Treatment Control Rocco (DB RCT) 31% 0.69 [0.40-1.17] 20/202 30/203 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.15 Late treatment 32% 0.68 [0.40-1.15] 20/219 46/230 32% lower risk All studies 28% 0.72 [0.43-1.21] 22/413 46/428 28% lower risk 3 nitazoxanide COVID-19 ICU results c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.22 ​1​ OT: comparison with other treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -2% 1.02 [0.30-3.47] hosp. 5/194 5/198 Improvement, RR [CI] Treatment Control Cadegiani 99% 0.01 [0.00-0.17] hosp. 0/357 27/137 Rossignol (DB RCT) 79% 0.21 [0.02-1.80] hosp. 1/184 5/195 Tau​2​ = 3.68, I​2​ = 78.4%, p = 0.16 Early treatment 83% 0.17 [0.01-2.00] 6/735 37/530 83% lower risk Blum (DB RCT) 56% 0.44 [0.22-0.89] hosp. time 25 (n) 25 (n) Improvement, RR [CI] Treatment Control Calderón 52% 0.48 [0.29-0.82] hosp. time 17 (n) 27 (n) OT​1​ Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.0004 Late treatment 53% 0.47 [0.31-0.71] 42 (n) 52 (n) 53% lower risk COVER Sokhela (RCT) 79% 0.21 [0.01-4.31] hosp. 0/240 2/265 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.31 Prophylaxis 79% 0.21 [0.01-4.31] 0/240 2/265 79% lower risk All studies 61% 0.39 [0.20-0.78] 6/1,017 39/847 61% lower risk 6 nitazoxanide COVID-19 hospitalization results c19early.org November 2024 Tau​2​ = 0.29, I​2​ = 47.9%, p = 0.0078 ​1​ OT: comparison with other treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Cadegiani 88% 0.12 [0.01-2.52] death 0/357 2/137 Rossignol (DB RCT) -206% 3.06 [0.13-74.6] death 1/184 0/195 ANTICOV ANTICOV (RCT) -188% 2.88 [1.05-7.85] progression 15/462 5/443 OT​1​ CT​2​ Chandiwana (RCT) -13% 1.13 [0.23-5.46] progression 37 (n) 39 (n) CT​2​ Tau​2​ = 0.18, I​2​ = 15.0%, p = 0.2 Early treatment -82% 1.82 [0.73-4.53] 18/1,234 7/1,012 82% higher risk Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Improvement, RR [CI] Treatment Control Calderón 68% 0.32 [0.04-2.49] death 1/17 5/27 OT​1​ Rocco (DB RCT) -5% 1.05 [0.30-3.50] death 6/202 5/203 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.23 Late treatment 40% 0.60 [0.26-1.39] 9/244 16/255 40% lower risk COVER Sokhela (RCT) 66% 0.34 [0.01-8.41] death 0/240 1/265 Improvement, RR [CI] Treatment Control Romark (DB RCT) 43% 0.57 [0.35-0.92] progression 13 (n) 13 (n) Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.017 Prophylaxis 44% 0.56 [0.35-0.90] 0/253 1/278 44% lower risk All studies 15% 0.85 [0.46-1.55] 27/1,731 24/1,545 15% lower risk 10 nitazoxanide COVID-19 serious outcomes c19early.org November 2024 Tau​2​ = 0.30, I​2​ = 37.6%, p = 0.6 Effect extraction pre-specified(most serious outcome) ​1​ OT: comparison with other treatment​2​ CT: study uses combined treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -16% 1.16 [0.84-1.59] no recov. 59/194 52/198 Improvement, RR [CI] Treatment Control Rossignol (DB RCT) -7% 1.07 [0.46-2.49] recov. time 184 (n) 195 (n) Chandiwana (RCT) -23% 1.23 [0.73-2.08] recov. time 37 (n) 39 (n) CT​1​ Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.23 Early treatment -17% 1.17 [0.91-1.51] 59/415 52/432 17% higher risk Fowotade (RCT) -11% 1.11 [0.61-2.03] no recov. 31 (n) 26 (n) CT​1​ Improvement, RR [CI] Treatment Control Rocco (DB RCT) 27% 0.73 [0.58-0.90] no disch. 202 (n) 203 (n) Tau​2​ = 0.04, I​2​ = 45.6%, p = 0.33 Late treatment 17% 0.83 [0.57-1.21] 233 (n) 229 (n) 17% lower risk Romark (DB RCT) 50% 0.50 [0.22-1.13] no recov. 13 (n) 13 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.097 Prophylaxis 50% 0.50 [0.22-1.13] 13 (n) 13 (n) 50% lower risk All studies 6% 0.94 [0.72-1.23] 59/661 52/674 6% lower risk 6 nitazoxanide COVID-19 recovery results c19early.org November 2024 Tau​2​ = 0.05, I​2​ = 51.0%, p = 0.67 ​1​ CT: study uses combined treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVER Sokhela (RCT) 17% 0.83 [0.50-1.40] symp. case 23/240 37/265 Improvement, RR [CI] Treatment Control Romark (DB RCT) 3% 0.97 [0.46-2.09] cases 13/629 13/613 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Prophylaxis 13% 0.87 [0.58-1.31] 36/869 50/878 13% lower risk All studies 13% 0.87 [0.58-1.31] 36/869 50/878 13% lower risk 2 nitazoxanide COVID-19 case results c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) 12% 0.88 [0.80-0.96] viral+ 194 (n) 198 (n) Improvement, RR [CI] Treatment Control Elalfy 87% 0.13 [0.06-0.27] viral+ 7/62 44/51 CT​1​ Silva (SB RCT) 26% 0.74 [0.38-1.41] viral+ 23 (n) 13 (n) Medhat (RCT) 56% 0.44 [0.22-0.88] viral+ 77 (n) 73 (n) Chandiwana (RCT) -67% 1.67 [0.85-3.23] viral+ 27/37 25/38 CT​1​ Tau​2​ = 0.37, I​2​ = 91.9%, p = 0.11 Early treatment 38% 0.62 [0.35-1.11] 34/393 69/373 38% lower risk Blum (DB RCT) 90% 0.10 [0.01-0.85] viral+ 0/23 4/19 Improvement, RR [CI] Treatment Control Fowotade (RCT) 5% 0.95 [0.34-2.64] viral load 31 (n) 26 (n) CT​1​ Tau​2​ = 1.31, I​2​ = 52.6%, p = 0.48 Late treatment 53% 0.47 [0.06-3.59] 0/54 4/45 53% lower risk All studies 38% 0.62 [0.37-1.05] 34/447 73/418 38% lower risk 7 nitazoxanide COVID-19 viral clearance results c19early.org November 2024 Tau​2​ = 0.35, I​2​ = 88.3%, p = 0.076 ​1​ CT: study uses combined treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Silva (SB RCT) 26% 0.74 [0.38-1.41] viral+ 23 (n) 13 (n) Rossignol (DB RCT) -206% 3.06 [0.13-74.6] death 1/184 0/195 ANTICOV ANTICOV (RCT) -188% 2.88 [1.05-7.85] progression 15/462 5/443 OT​1​ CT​2​ Medhat (RCT) 56% 0.44 [0.22-0.88] viral+ 77 (n) 73 (n) Chandiwana (RCT) -13% 1.13 [0.23-5.46] progression 37 (n) 39 (n) CT​2​ FANTAZE Smith (DB RCT) unknown, >1.5 years late 120 (total) Tau​2​ = 0.39, I​2​ = 56.0%, p = 0.87 Early treatment -7% 1.07 [0.51-2.23] 18/977 5/961 7% higher risk Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Improvement, RR [CI] Treatment Control Fowotade (RCT) -11% 1.11 [0.61-2.03] no recov. 31 (n) 26 (n) CT​2​ Rocco (DB RCT) -5% 1.05 [0.30-3.50] death 6/202 5/203 Tau​2​ = 0.03, I​2​ = 8.5%, p = 0.86 Late treatment 5% 0.95 [0.55-1.63] 8/258 11/254 5% lower risk COVER Sokhela (RCT) 66% 0.34 [0.01-8.41] death 0/240 1/265 Improvement, RR [CI] Treatment Control Romark (DB RCT) 43% 0.57 [0.35-0.92] progression 13 (n) 13 (n) Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.017 Prophylaxis 44% 0.56 [0.35-0.90] 0/253 1/278 44% lower risk All studies 17% 0.83 [0.57-1.23] 26/1,488 17/1,493 17% lower risk 11 nitazoxanide COVID-19 Randomized Controlled Trials c19early.org November 2024 Tau​2​ = 0.14, I​2​ = 39.0%, p = 0.36 Effect extraction pre-specified(most serious outcome) ​1​ OT: comparison with other treatment​2​ CT: study uses combined treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rossignol (DB RCT) -206% 3.06 [0.13-74.6] 1/184 0/195 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.5 Early treatment -206% 3.06 [0.13-74.6] 1/184 0/195 206% higher risk Blum (DB RCT) 67% 0.33 [0.07-1.50] 2/25 6/25 Improvement, RR [CI] Treatment Control Rocco (DB RCT) -5% 1.05 [0.30-3.50] 6/202 5/203 Tau​2​ = 0.19, I​2​ = 28.2%, p = 0.46 Late treatment 35% 0.65 [0.22-1.98] 8/227 11/228 35% lower risk COVER Sokhela (RCT) 66% 0.34 [0.01-8.41] 0/240 1/265 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Prophylaxis 66% 0.34 [0.01-8.41] 0/240 1/265 66% lower risk All studies 28% 0.72 [0.31-1.70] 9/651 12/688 28% lower risk 4 nitazoxanide COVID-19 RCT mortality results c19early.org November 2024 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.46 Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Cadegiani 88% 0.12 [0.01-2.52] death 0/357 2/137 Elalfy 87% 0.13 [0.06-0.27] viral+ 7/62 44/51 CT​2​ Silva (SB RCT) 26% 0.74 [0.38-1.41] viral+ 23 (n) 13 (n) Rossignol (DB RCT) -206% 3.06 [0.13-74.6] death 1/184 0/195 Medhat (RCT) 56% 0.44 [0.22-0.88] viral+ 77 (n) 73 (n) Chandiwana (RCT) -13% 1.13 [0.23-5.46] progression 37 (n) 39 (n) CT​2​ Tau​2​ = 0.67, I​2​ = 69.3%, p = 0.12 Early treatment 49% 0.51 [0.22-1.18] 10/934 46/706 49% lower risk Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Improvement, RR [CI] Treatment Control Calderón 68% 0.32 [0.04-2.49] death 1/17 5/27 OT​1​ Rocco (DB RCT) -5% 1.05 [0.30-3.50] death 6/202 5/203 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.23 Late treatment 40% 0.60 [0.26-1.39] 9/244 16/255 40% lower risk COVER Sokhela (RCT) 66% 0.34 [0.01-8.41] death 0/240 1/265 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.52 Prophylaxis 66% 0.34 [0.01-8.41] 0/240 1/265 66% lower risk All studies 50% 0.50 [0.27-0.91] 19/1,418 63/1,226 50% lower risk 11 nitazoxanide COVID-19 peer reviewed studies c19early.org November 2024 Tau​2​ = 0.45, I​2​ = 54.7%, p = 0.024 Effect extraction pre-specified(most serious outcome) ​1​ OT: comparison with other treatment​2​ CT: study uses combined treatment Favors nitazoxanide Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Rocco (RCT) -404% 5.04 [0.24-104] ICU 2/194 0/198 Improvement, RR [CI] Treatment Control Rocco (RCT) -2% 1.02 [0.30-3.47] hosp. 5/194 5/198 Rocco (RCT) -16% 1.16 [0.84-1.59] no recov. 59/194 52/198 Rocco (RCT) 12% 0.88 [0.80-0.96] viral+ 194 (n) 198 (n) Rocco (RCT) 14% 0.86 [0.77-0.96] viral+ 136/194 162/198 Cadegiani 88% 0.12 [0.01-2.52] death 0/357 2/137 Cadegiani 97% 0.03 [0.00-0.51] ventilation 0/357 9/137 Cadegiani 99% 0.01 [0.00-0.17] hosp. 0/357 27/137 Elalfy 87% 0.13 [0.06-0.27] viral+ 7/62 44/51 CT​2​ Elalfy 58% 0.42 [0.31-0.56] viral+ 26/62 51/51 CT​2​ Silva (SB RCT) 26% 0.74 [0.38-1.41] viral+ 23 (n) 13 (n) Silva (SB RCT) 38% 0.62 [0.36-1.05] viral+ 12/23 11/13 Rossignol (DB RCT) -206% 3.06 [0.13-74.6] death 1/184 0/195 Rossignol (DB RCT) 79% 0.21 [0.02-1.80] hosp. 1/184 5/195 Rossignol (DB RCT) 85% 0.15 [0.02-1.22] severe case 1/184 7/195 Rossignol (DB RCT) 84% 0.16 [0.02-1.29] severe case 1/112 7/126 Rossignol (DB RCT) -7% 1.07 [0.46-2.49] recov. time 184 (n) 195 (n) ANTICOV ANTICOV (RCT) -188% 2.88 [1.05-7.85] progression 15/462 5/443 OT​1​ CT​2​ Medhat (RCT) 56% 0.44 [0.22-0.88] viral+ 77 (n) 73 (n) Chandiwana (RCT) -13% 1.13 [0.23-5.46] progression 37 (n) 39 (n) CT​2​ Chandiwana (RCT) -23% 1.23 [0.73-2.08] recov. time 37 (n) 39 (n) CT​2​ Chandiwana (RCT) -67% 1.67 [0.85-3.23] viral+ 27/37 25/38 CT​2​ Blum (DB RCT) 67% 0.33 [0.07-1.50] death 2/25 6/25 Blum (DB RCT) 62% 0.38 [0.11-1.25] ventilation 3/25 8/25 Blum (DB RCT) 56% 0.44 [0.22-0.89] hosp. time 25 (n) 25 (n) Blum (DB RCT) 90% 0.10 [0.01-0.85] viral+ 0/23 4/19 Calderón 68% 0.32 [0.04-2.49] death 1/17 5/27 OT​1​ Calderón 87% 0.13 [0.01-2.33] ventilation 0/17 4/27 OT​1​ Calderón 59% 0.41 [0.25-0.59] ICU 0/17 16/27 OT​1​ Calderón 52% 0.48 [0.29-0.82] hosp. time 17 (n) 27 (n) OT​1​ Fowotade (RCT) -11% 1.11 [0.61-2.03] no recov. 31 (n) 26 (n) CT​2​ Fowotade (RCT) -87% 1.87 [0.88-3.98] no recov. 31 (n) 26 (n) CT​2​ Fowotade (RCT) 5% 0.95 [0.34-2.64] viral load 31 (n) 26 (n) CT​2​ Rocco (DB RCT) -5% 1.05 [0.30-3.50] death 6/202 5/203 Rocco (DB RCT) 31% 0.69 [0.40-1.17] ICU 20/202 30/203 Rocco (DB RCT) 40% 0.60 [0.35-1.02] oxygen 22/202 33/203 Rocco (DB RCT) 64% 0.36 [0.29-0.45] no improv. 202 (n) 203 (n) Rocco (DB RCT) 34% 0.66 [0.38-1.15] no improv. 202 (n) 203 (n) Rocco (DB RCT) 27% 0.73 [0.58-0.90] no disch. 202 (n) 203 (n) Rocco (DB RCT) 8% 0.92 [0.55-1.52] no disch. 202 (n) 203 (n) COVER Sokhela (RCT) 66% 0.34 [0.01-8.41] death 0/240 1/265 COVER Sokhela (RCT) 79% 0.21 [0.01-4.31] hosp. 0/240 2/265 COVER Sokhela (RCT) 17% 0.83 [0.50-1.40] symp. case 23/240 37/265 COVER Sokhela (RCT) -21% 1.21 [0.29-1.58] cases 23/240 37/265 Romark (DB RCT) 43% 0.57 [0.35-0.92] progression 13 (n) 13 (n) Romark (DB RCT) 50% 0.50 [0.22-1.13] no recov. 13 (n) 13 (n) Romark (DB RCT) 32% 0.68 [0.32-1.45] no recov. 13 (n) 13 (n) Romark (DB RCT) 28% 0.72 [0.29-1.78] no recov. 13 (n) 13 (n) Romark (DB RCT) 3% 0.97 [0.46-2.09] cases 13/629 13/613 Nitazoxanide COVID-19 outcomes c19early.org November 2024 ​1​ OT: comparison with other treatment​2​ CT: study uses combined treatment Favors nitazoxanide Favors control
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0